Biodel
Quick facts
Marketed products
- Humalog Mix 75/25 · Diabetes
Humalog Mix 75/25 is a combination insulin product that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes. - recombinant human insulin · Diabetes
Recombinant human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Phase 3 pipeline
- Insulin VIAject™ (75%) · Diabetes
Insulin VIAject is a rapid-acting insulin formulation designed to be absorbed faster than standard insulin injections, allowing for quicker onset of action and better postprandial glucose control. - Insulin VIAject™ (90%) · Diabetes
Insulin VIAject is a rapid-acting insulin formulation designed to achieve faster absorption and onset of action compared to standard insulin injections. - VIAject™ · Diabetes
VIAject is a rapid-acting insulin formulation that uses a proprietary excipient system to accelerate insulin absorption and onset of action. - Viaject 7 · Diabetes
Viaject 7 is a recombinant human insulin analog.
Phase 2 pipeline
- BIOD-123 · Diabetes
BIOD-123 is a rapid-acting insulin formulation designed to improve postprandial glucose control in diabetes patients. - VIAject 50%
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: